Skip to the answer

Treprostinil Uses, Dosage, Side Effects and Interactions

Brand names
Orenitram

Orenitram came 11 years after Remodulin (December 2013) as an extended-release tablet, a form not listed for Remodulin. No generic is listed as extended-release tablets, though generic treprostinil is listed as injections.

First generic of Orenitram: our estimate, June 2027

Tyvaso

Tyvaso came 7 years after Remodulin (July 2009) as an inhalation solution (nebulizer), a form not listed for Remodulin. No generic is listed as inhalers, though generic treprostinil is listed as injections.

First generic of Tyvaso: our estimate, sometime in 2026

Remodulin

Remodulin was the first treprostinil product the FDA approved, in May 2002. An FDA-approved generic with the same active ingredient is listed.

Yutrepia

Yutrepia came 23 years after Remodulin (May 2025) as an inhalation powder, a form not listed for Remodulin. No generic is listed as inhalers, though generic treprostinil is listed as injections.

Tyvaso DPI

Tyvaso DPI came 20 years after Remodulin (May 2022) as an inhalation powder, a form not listed for Remodulin. No generic is listed as inhalers, though generic treprostinil is listed as injections.

Treprostinil is a prostacyclin-based medicine used to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), available in inhaled, oral, and injectable forms.

Dr. Brian Staiger, PharmD, BCPS
Last reviewed Jul 10, 2026 Content updated Nov 7, 2026 Where our facts come from

Quick links

Ask Anything About TreprostinilType a question in your own words. Answered from its FDA label in seconds.

Every other section of this page is in the dots on the left edge of your screen: point at one to see where it goes.Every other section of this page is one tap away: use the arrow tab on the left edge of your screen.

Treprostinil in Short

The Pharmacist’s Take

Dr. Brian Staiger, PharmD, BCPS
Clinical pharmacist Written

Treprostinil is a specialist medicine for pulmonary arterial hypertension (PAH, high blood pressure in the lung arteries) and, in inhaled form, for pulmonary hypertension from interstitial lung disease (lung scarring). It copies a natural substance called prostacyclin to widen lung blood vessels and slow platelets (clotting cells) from clumping, and it has been used since about 2002, with FDA-approved generics listed. Side effects are common, mainly headache, flushing, jaw pain and nausea, plus pain at the site with infusions under the skin. Above all, never let it stop suddenly, since PAH can worsen fast, and with IV use treat fever or chills as an urgent sign of bloodstream infection.

Key Takeaways From the HelloPharmacist Team

  • Expect inhaler sessions several times daily, tablets with food two or three times daily, or a nonstop infusion pump, depending on your form.
  • Order refills early and keep backup supplies on hand, because running out even briefly can make PAH worsen quickly.
  • Get help right away for fainting, marked dizziness or unusual bleeding, since it lowers blood pressure and blunts platelet clumping.
  • Tell your team before starting gemfibrozil or rifampin, which raise or lower treprostinil levels, and about any blood pressure medicines.

How we write and review this content: our editorial policy

Treprostinil by the Numbers

Strengths
20
across 3 forms
Makers and packagers
6
Earliest FDA record
2002
Rank by Medicaid prescriptions
#863 of 1,682 drugs
More prescriptions than 48% of the 1,682 drugs we measure
15,732 prescriptions, Q1–Q4 2025
Other forms and routes

Patient Information Guide for Treprostinil

What It’s Used For

Treprostinil is approved for use across several products and routes. Here is the full set of supported indications:

  • Pulmonary arterial hypertension (PAH; WHO Group 1) — improving exercise ability: Supported by Tyvaso, Tyvaso DPI, Yutrepia (inhaled), and treprostinil injection / Remodulin (subcutaneous or IV)
  • PAH (WHO Group 1) — delaying disease progression and improving exercise capacity: Orenitram (extended-release oral tablet) only
  • PAH (WHO Group 1) — transitioning patients from epoprostenol: Treprostinil injection and Remodulin only
  • Pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) — improving exercise ability: Tyvaso, Tyvaso DPI, and Yutrepia (inhaled forms) only

How It Works

Treprostinil mimics a natural substance in the body called prostacyclin. It works by directly relaxing and widening the blood vessels in the lungs and throughout the body, which lowers the pressure the heart has to pump against. It also reduces the tendency of platelets (the tiny blood cells that form clots) to clump together, and may help slow the abnormal thickening of blood vessel walls that characterizes PAH.

Drug Class

Drug Class

  • Prostacycline Vasodilator
Detailed classifications and sources

The FDA sorts a drug’s active ingredient by how it works, what it does in the body and its chemical structure, and gives it one main drug class.

Drug Class

Established Pharmacologic Class (EPC)
  • Prostacycline Vasodilator

The main drug class the FDA gives it. It is the class named on the drug’s label.

How It Works

Mechanism of action (MoA)

None listed for Treprostinil in the FDA’s index.

What it does at the smallest level, such as a receptor or enzyme it blocks or switches on.

What It Does in the Body

Physiologic effect (PE)
  • Vasodilation

A change it makes in how the body works.

Chemical Family

Chemical structure (CS)
  • Prostaglandins I

The chemical family it belongs to, by its structure.

Drug Family

WHO ATC classification
  • Platelet aggregation inhibitors excl. heparin

How the World Health Organization groups it: by the part of the body it acts on and what it treats.

The classes are the FDA’s own words, from its index of drug labels, published in the National Library of Medicine’s RxClass. Read the FDA’s definitions. The drug family is the World Health Organization’s ATC classification. Reference only, not medical advice.

Dosage

How treprostinil is taken varies significantly by product — always follow your prescriber's specific instructions.

  • Orenitram (tablet): Taken by mouth with food, multiple times per day; tablets must be swallowed whole
  • Tyvaso (inhaled solution): Inhaled using the Tyvaso Inhalation System in 4 sessions per day, spaced about 4 hours apart during waking hours
  • Tyvaso DPI (inhaled powder): Inhaled using the Tyvaso DPI Inhaler in 4 sessions per day, approximately 4 hours apart
  • Yutrepia (inhaled capsule): Inhaled — not swallowed — using the supplied device, 3 to 5 times per day
  • Remodulin / treprostinil injection: Given as a continuous infusion under the skin or into a vein, around the clock; doses are increased gradually

Never stop treprostinil suddenly or miss large portions of your dose without speaking to your doctor first — abrupt changes can be dangerous.

Typical Doses

Your prescriber chooses your dose, so take it exactly as prescribed.

Treprostinil Injection

Pulmonary arterial hypertension (high blood pressure in the lungs)
Adults new to prostacyclin infusion therapy · Starting dose 1.25 ng/kg/min continuous subcutaneous or intravenous infusion; if not tolerated because of systemic effects, reduce to 0.625 ng/kg/min

Good to know

Subcutaneous preferred; IV if subcutaneous not tolerated

IV means given into a vein (intravenous).

Adults · Dose increases Increase infusion rate by 1.25 ng/kg/min per week for the first four weeks of treatment, then 2.5 ng/kg/min per week, depending on clinical response; avoid abrupt cessation
Adults switching from epoprostenol · Step 1 Remodulin 10% Starting Epoprostenol Dose; epoprostenol unchanged

Good to know

In a hospital with constant observation

Adults switching from epoprostenol · Step 2 Remodulin 30% Starting Epoprostenol Dose; epoprostenol 80% Starting Epoprostenol Dose
Adults switching from epoprostenol · Step 3 Remodulin 50% Starting Epoprostenol Dose; epoprostenol 60% Starting Epoprostenol Dose
Adults switching from epoprostenol · Step 4 Remodulin 70% Starting Epoprostenol Dose; epoprostenol 40% Starting Epoprostenol Dose
Adults switching from epoprostenol · Step 5 Remodulin 90% Starting Epoprostenol Dose; epoprostenol 20% Starting Epoprostenol Dose
Adults switching from epoprostenol · Step 6 Remodulin 110% Starting Epoprostenol Dose; epoprostenol 5% Starting Epoprostenol Dose
Adults switching from epoprostenol · Step 7 Remodulin 110% Starting Epoprostenol Dose + additional 5-10% increments as needed; epoprostenol 0
Adults with mild or moderate liver problems · Starting dose Decrease initial dose to 0.625 ng/kg/min ideal body weight

Good to know

Not studied in severe hepatic insufficiency

See the Full Dosing Instructions on DailyMed →

Treprostinil Taken by Mouth

Pulmonary arterial hypertension (high blood pressure in the lungs)
Adults · Starting dose · Three times Starting dose 0.125 mg three times a day Highest dose 120 mg a day

Step by step

  1. 0.125 mg three times daily with food, about 8 hours apart
  2. Titrate by 0.125 mg three times daily not more often than every 3 to 4 days

Good to know

Swallow whole with food

Adults · Starting dose · Twice Starting dose 0.25 mg twice a day Highest dose 120 mg a day

Step by step

  1. 0.25 mg twice daily with food, about 12 hours apart
  2. Titrate by 0.25 or 0.5 mg twice daily not more often than every 3 to 4 days

Good to know

Swallow whole with food

Adults with mild liver problems or taking strong CYP2C8 inhibitors · Starting dose Starting dose 0.125 mg twice a day
  • Start at 0.125 mg twice daily, with 0.125 mg twice daily increments not more often than every 3 to 4 days

Good to know

Avoid in moderate impairment; contraindicated in severe

See the Full Dosing Instructions on DailyMed →

Tyvaso DPI

Pulmonary arterial hypertension or lung high blood pressure from lung scarring disease
Adults · Starting dose Starting dose 16 mcg 4 times a day
  • One 16 mcg cartridge per treatment session, 4 times daily, about 4 hours apart
  • Single inhalation per cartridge
Adults · Maintenance dose Usual dose 48 mcg to 64 mcg 4 times a day
  • Increase by 16 mcg per session at about 1- to 2-week intervals
  • Target 48 mcg to 64 mcg per session, 4 times daily

See the Full Dosing Instructions on DailyMed →

Yutrepia

Pulmonary arterial hypertension (high blood pressure in the lungs)
Adults new to treprostinil Starting dose 26.5 mcg 3 to 5 times a day Usual dose 79.5 mcg to 106 mcg 4 times a day

Step by step

  1. 26.5 mcg 3 to 5 times per day, in 2 breaths
  2. Increase by 26.5 mcg per dose each week as tolerated
  3. Target 79.5 mcg to 106 mcg 4 times daily
  4. Doses above 848 mcg per day have not been studied
Adults switching from Tyvaso · 5 or less breaths Starting dose 26.5 mcg 3 to 5 times a day
  • 26.5 mcg, 3 to 5 times per day, in 2 breaths
Adults switching from Tyvaso · 6 to 8 breaths Starting dose 53 mcg 3 to 5 times a day
  • 53 mcg, 3 to 5 times per day, in 2 breaths
Adults switching from Tyvaso · 9 to 11 breaths Starting dose 79.5 mcg 3 to 5 times a day
  • 79.5 mcg, 3 to 5 times per day, in 2 breaths
Adults switching from Tyvaso · 12 to 14 breaths Starting dose 106 mcg 3 to 5 times a day
  • 106 mcg, 3 to 5 times per day, in 2 breaths
Adults switching from Tyvaso · 15 to 17 breaths Starting dose 132.5 mcg 3 to 5 times a day
  • 132.5 mcg, 3 to 5 times per day, in 2 breaths
Adults switching from Tyvaso · 18 or more breaths Starting dose 159 mcg 3 to 5 times a day
  • 159 mcg, 3 to 5 times per day, in 2 breaths

See the Full Dosing Instructions on DailyMed →

Tyvaso

Pulmonary arterial hypertension or lung high blood pressure from lung scarring disease
Adults · Starting dose Starting dose 3 breaths (18 mcg) 4 times a day
  • 3 breaths (18 mcg) per treatment session, 4 times daily
  • If not tolerated, reduce to 1 or 2 breaths
Adults · Maintenance dose Increase by 3 breaths per session at about 1- to 2-week intervals; target 9 to 12 breaths per session, 4 times daily

See the Full Dosing Instructions on DailyMed →

Side Effects

Side effects vary by route, but here are the most commonly reported ones across treprostinil products:

Common side effects

  • Infusion site pain and skin reaction (with injectable forms)
  • Headache
  • Diarrhea
  • Nausea
  • Jaw pain
  • Flushing or vasodilation (feeling of warmth, skin redness)
  • Swelling (edema)
  • Low blood pressure (hypotension)
  • Rash

When to get medical help

  • Call your doctor or seek emergency care if you develop signs of a bloodstream infection: fever, chills, or feeling very unwell — especially with IV infusion
  • Do not suddenly stop or sharply reduce your dose; this can cause a rapid worsening of PAH symptoms
  • Get immediate help if you feel faint, dizzy, or have a significant drop in blood pressure
  • Tell your doctor right away if you notice unusual or prolonged bleeding, as treprostinil affects platelet function
  • Seek care promptly for any signs of severe infection at the catheter or infusion site

Warnings and Precautions

  • Risk of serious bloodstream infection with IV use: Long-term IV infusion through a central venous catheter carries a risk of life-threatening blood infections and sepsis. Subcutaneous infusion is preferred for this reason. Watch for fever, chills, or sudden worsening and seek care immediately.
  • Never stop abruptly: Suddenly stopping or sharply reducing the dose can cause a rapid, dangerous worsening of PAH symptoms. Any dose changes must be made with medical guidance.
  • Low blood pressure risk: Treprostinil widens blood vessels throughout the body, which can cause symptomatic low blood pressure — especially in patients who already have low systemic blood pressure.
  • Increased bleeding risk: Because treprostinil inhibits platelet aggregation (clumping), it can increase the tendency to bleed. Report unusual bruising or bleeding to your doctor.
  • Liver disease caution: In patients with liver problems, treprostinil clears much more slowly, leading to higher drug levels and greater risk of side effects. Dose must be adjusted carefully; use is contraindicated in severe liver impairment.

Interactions

Treprostinil can be affected by certain other medicines — tell your prescriber and pharmacist everything you take:

  • Gemfibrozil (cholesterol medicine): Blocks the liver enzyme (CYP2C8) that clears treprostinil, roughly doubling drug levels — a significant interaction requiring medical attention
  • Rifampin (antibiotic): Speeds up treprostinil clearance through the same enzyme, reducing how much is in your body and potentially making it less effective
  • Blood pressure medicines and other vasodilators: Can add to treprostinil's blood pressure-lowering effect, increasing the risk of hypotension
  • Warfarin (blood thinner): Treprostinil does not appear to change warfarin levels or its INR effect, but treprostinil's own platelet-inhibiting action means bleeding risk should still be monitored
  • Bosentan and sildenafil: No significant pharmacokinetic interaction found in studies; these are frequently prescribed alongside treprostinil but your full medicine list should always be reviewed by your care team

Interactions Listed in the FDA-Approved Label

From the Treprostinil prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.

  • What happensNo pharmacokinetic interactions between treprostinil and bosentan were observed.
  • What happensNo pharmacokinetic interactions between treprostinil and sildenafil were observed.
  • What happensIncreases exposure (Cmax and AUC) to oral treprostinil.
    What to doWith strong CYP2C8 inhibitors, oral initial dose is 0.125 mg BID.
  • What happensDecreases exposure to treprostinil.
  • What happensNo clinically significant effect on treprostinil pharmacokinetics.
  • What happensNo effect on warfarin pharmacokinetics or INR; no clinically significant effect on treprostinil.
  • What happensNo clinically significant effect on treprostinil pharmacokinetics.
Read the label’s full interactions text

7 DRUG INTERACTIONS • Treprostinil injection dosage adjustment may be necessary if inhibitors or inducers of CYP2C8 are added or withdrawn. 7.1 Effect of CYP2C8 Inhibitors and Inducers on Treprostinil Dose adjustment of treprostinil may be necessary when co-administered with CYP2C8 inducers or inhibitors. Human pharmacokinetic studies with an oral formulation of treprostinil (treprostinil diolamine) indicated that co-administration of the cytochrome P450 (CYP) 2C8 enzyme inhibitor gemfibrozil increases exposure (both C max and AUC) to treprostinil. Co-administration of the CYP2C8 enzyme inducer rifampin decreases exposure to treprostinil. It has not been determined if the changes in exposure of treprostinil with inhibitors or inducers of CYP2C8 observed for the oral administration of treprostinil would be similar for treprostinil administered via the parenteral route.

Read the full Drug Interactions section on DailyMed →

Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.

Before You Start

  • Severe liver impairment (Child-Pugh Class C): Treprostinil is contraindicated — it cannot be used safely
  • Moderate liver impairment: Orenitram should be avoided; other forms require extra caution and lower starting doses
  • Mild liver impairment: Use with caution; lower starting doses and slow titration are required
  • Pregnancy: Animal studies showed fetal harm at relatively low doses; PAH in pregnancy itself carries serious risks to mother and baby — discuss risks and benefits carefully with your doctor before or if you become pregnant
  • Breastfeeding: It is unknown whether treprostinil passes into human milk; discuss with your doctor
  • Children: Safety and effectiveness have not been established in pediatric patients
  • Older adults: Higher rates of side effects have been observed; dose selection should be cautious, accounting for possible reduced liver or heart function
  • Kidney disease: No dose adjustment is required; treprostinil is not removed by dialysis

Overdose

Too much treprostinil causes an exaggerated version of its normal effects: flushing, headache, low blood pressure, nausea, vomiting, and diarrhea. In serious cases — particularly if a large accidental dose is delivered through an IV catheter — severe low blood pressure, near-fainting, or seizure-like activity can occur. Most overdose events in clinical trials resolved when the infusion was slowed or stopped. If you suspect an overdose, seek emergency medical care immediately.

Half-Life and How Your Body Processes It

When given by subcutaneous infusion, treprostinil is almost completely absorbed, reaching steady drug levels in roughly 10 hours. It is about 91% bound to proteins in the blood and is broken down primarily in the liver by an enzyme called CYP2C8. Most of the drug and its inactive breakdown products leave the body through the urine. The drug's half-life — the time it takes for the body to clear half of it — is approximately 4 hours after subcutaneous dosing. In patients with liver disease, clearance can be reduced by up to 80%, causing drug levels to build much higher than normal.

Storage

Stored at 25°C (77°F), with excursions permitted to 2° to 30°C (36° to 86°F).

Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI

Supplements and Herbs That Interact With Treprostinil

From the licensed clinical database we use, rolled up per supplement, most serious first.

292 supplements and herbal products have documented interactions with Treprostinil in the licensed clinical database we use.

Most are manageable, but your pharmacist should know about everything you take, including vitamins and herbals.

  • 5Major
  • 261Moderate
  • 26Minor

See the other 284

Educational information from a licensed clinical database (Natural Medicines). See our data sources and update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.

Nutrients Treprostinil May Deplete

Nutrients Treprostinil has been linked with lower levels of, from the licensed clinical database we use.

Treprostinil has been associated with lower levels of 1 nutrient in the clinical literature. This does not mean a deficiency will occur. It means these may be worth discussing with your pharmacist or healthcare provider, especially with long-term use.

Educational information from a licensed clinical database (Natural Medicines), not medical advice. Do not start or stop medications or supplements without professional guidance.

Treprostinil: Pharmacist Answers to Common Questions

Quick, plain-English answers to the questions patients ask most about Treprostinil — the kind of thing our pharmacy team would talk through with you at the counter.

What exactly is treprostinil and why did my doctor prescribe it?

Treprostinil mimics a natural substance your body makes to keep blood vessel walls relaxed. In pulmonary arterial hypertension (PAH) — and in some lung-disease-related forms of high lung pressure — those vessels become too narrow and stiff, forcing your heart to work dangerously hard. Treprostinil widens those vessels, lowers that pressure, and helps you tolerate activity better. Depending on which product you're on, it may also be aimed at slowing how fast your disease progresses.

I'm on the inhaled version — how often do I need to use it each day?

The inhaled products are all used multiple times per day, spaced out across your waking hours. Tyvaso and Tyvaso DPI are typically used 4 times a day, roughly 4 hours apart. Yutrepia is used 3 to 5 times a day. The timing can be shifted a bit around planned activities since the effect does taper between sessions. Your prescriber and the instructions that come with your device will spell out the exact routine — stick to that schedule as closely as you can.

What side effects should I expect, and which ones mean I need to call someone?

Headache, jaw pain, flushing, nausea, and diarrhea are common and tend to be most noticeable when your dose is being increased. If you're on the subcutaneous (under-the-skin) injection, site pain and redness are very common and can sometimes be quite bothersome. These effects are generally related to the drug relaxing blood vessels and tend to settle over time. Call your doctor or seek emergency care if you feel significantly dizzy or faint from low blood pressure, notice unusual bleeding, or — if you're on IV treprostinil — develop fever, chills, or signs of an infection.

Can I ever just stop taking it if I feel like I need a break?

Please don't stop suddenly on your own — this is one of the most important things to know about treprostinil. Abruptly stopping or sharply cutting the dose can cause your PAH symptoms to worsen quickly and dangerously. If you're having side effects or struggling with the treatment, call your care team and they can help you adjust things safely. Any changes to your dose should always be made with medical guidance.

Are there medicines or supplements I should avoid while taking treprostinil?

Yes — a few are worth flagging. Gemfibrozil, used for cholesterol, can roughly double the amount of treprostinil in your blood, raising the risk of side effects. Rifampin, an antibiotic, can push levels in the opposite direction and make treprostinil less effective. Any medicine that lowers blood pressure can add to treprostinil's own blood pressure-lowering effect. Make sure your full medicine list — including over-the-counter drugs and supplements — is reviewed by your pharmacist or prescriber.

Is it safe to get pregnant or breastfeed while on treprostinil?

This is a really important conversation to have with your doctor before trying to get pregnant. Animal studies showed treprostinil can harm fetal development, and PAH itself carries serious risks during pregnancy — including heart failure, preterm birth, and stillbirth. As for breastfeeding, we don't currently have data on whether treprostinil passes into breast milk. Your care team can help you weigh the risks and benefits based on your specific situation.

Is treprostinil available over the counter?

No. Treprostinil is a prescription medicine: every treprostinil product listed with the FDA is prescription only, so it is not sold over the counter. Your prescriber decides whether it is appropriate for you, and your pharmacist dispenses it.

When was treprostinil first available?

The earliest FDA record we hold for treprostinil is from 2002: its first approval in Drugs@FDA or its earliest product listing in the NDC Directory, whichever is older. Many older medicines were in use before their first formal FDA approval, so this is the earliest date on record, not necessarily when treprostinil was first used.

Who makes treprostinil?

6 companies currently list treprostinil products in the FDA's NDC Directory, including United Therapeutics Corporation, Alembic Pharmaceuticals Inc., Dr.Reddy's Laboratories Inc.,. That count includes repackagers and distributors as well as manufacturers (companies that sell only the raw ingredient are not counted), so fewer companies actually make it; the label on your bottle names the one that supplied yours.

What is the brand name of treprostinil?

Treprostinil is the generic name. Its brand names are Orenitram, Tyvaso, Remodulin, Yutrepia and Tyvaso DPI. Generic versions are listed under the name treprostinil.

What is the generic name of Orenitram?

The generic name of Orenitram is treprostinil. A generic name is the name of the active ingredient, the same whichever company makes the medicine; a brand name belongs to one company. Your prescription label may show either name.

What drug class is treprostinil?

Treprostinil belongs to the drug class Prostacycline Vasodilator, its established pharmacologic class on the FDA label.

Is there a generic version of treprostinil?

Yes. FDA-approved generic versions of treprostinil are listed in the FDA's National Drug Code Directory. A listing does not prove that every pharmacy stocks one, so your pharmacy can tell you which version it carries.

What strengths does treprostinil come in?

Treprostinil is listed in the FDA's National Drug Code Directory in these forms and strengths. Injection (into a vein, under the skin): 8 mg/20 mL, 20 mg/20 mL, 50 mg/20 mL, 100 mg/20 mL and 200 mg/20 mL. Extended-release tablet (by mouth): 0.125 mg, 0.25 mg, 1 mg, 2.5 mg and 5 mg. Inhaler (by mouth, inhaled): 16 mcg, 26.5 mcg, 32 mcg, 48 mcg, 53 mcg, 64 mcg, 79.5 mcg, 80 mcg, 106 mcg and 1.74 mg/2.9 mL. A listing does not mean every pharmacy stocks every strength.

How much does treprostinil cost?

What you pay depends on your insurance, your pharmacy and the strength you take. As a benchmark, state Medicaid programs paid an average of $8.17 to $307.42 per extended-release tablet of brand-name Orenitram across 5 strengths (most strengths about $60.20) over the four quarters through Q1 2026 (CMS's State Drug Utilization Data), before the rebates drug makers pay Medicaid. CMS's weekly pharmacy survey (NADAC) has no price for it, and Medicaid's figure is what a program paid, not the price at the counter. No national price was found for treprostinil injections or inhalers. The pharmacy prices section of this page lists every strength priced.

Is there a treprostinil shortage?

No. Treprostinil is not on the FDA's drug shortage list as of Nov 21, 2026. A single pharmacy can still run short for a while without a national shortage, and your pharmacist can tell you what they are seeing.

Where can I read the treprostinil prescribing information (package insert)?

The full FDA-approved prescribing information for treprostinil, also called the package insert or drug label, is published on DailyMed, the National Library of Medicine's library of FDA labels. Each company's version has its own label; this page is built from Alembic Pharmaceuticals Inc.'s, revised Feb 13, 2025, and links to it on DailyMed.

Can you crush treprostinil?

One form of treprostinil is on our Do Not Crush list of tablets and capsules that should not be crushed or chewed: Orenitram (tablet, extended release). An extended-release form releases the medicine over many hours, and crushing or chewing it can release the whole dose at once. A form that is not on the list may still come with its own instructions, so check the label and ask your pharmacist before you crush, split or open any medicine. Each listed form’s reason and instructions are on our Do Not Crush list.

Is treprostinil gluten free?

No treprostinil label we read lists an ingredient made from wheat, barley or rye, the grains that carry gluten. We read the FDA labels of 41 treprostinil products from 6 companies. Of those, 5 name a starch, dextrin or maltodextrin without saying where it comes from, so for those the answer is "source unclear", not "no". A label lists ingredients; it is not a gluten test, so we cannot promise that any product has no gluten. If you have celiac disease, ask the company for a written gluten statement. Our Inactive Ingredient Checker shows each company's treprostinil by strength and NDC, and whether its label lists a gluten source, lactose, dyes or any other inactive ingredient. See treprostinil inactive ingredients by company

Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI

Ask Anything About Treprostinil

Skip the scrolling. Ask in your own words and get an answer from Treprostinil’s FDA label and our pharmacists’ own work.

Try:

Name another drug or a supplement in your question and we check both.

AI answers from FDA labels and our own records, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.How this works
  • Sources: Treprostinil’s FDA label, including the clinical studies it reports, and the label of any drug you name; our pharmacists’ own work, such as our Do Not Crush list and our published answers to readers’ questions; our pharmacy prices and the Natural Medicines supplement database.
  • Written by AI: Answers are written by AI from those sources, and AI can make mistakes. Check what you read here with your doctor or pharmacist before you act on it.
  • Reviewed afterward: Our pharmacy team reviews every question and answer afterward to check it for accuracy, and when we find an error, we correct how the box answers. Read more in How we use AI.
  • Not medical advice. In an emergency, call 911, Poison Control at 1-800-222-1222, or 988.

More About Treprostinil on HelloPharmacist

Still have a question? A licensed pharmacist answers for free, as soon as they can.
Detailed Data & References for Treprostinil Forms and strengths, pricing, billing codes, manufacturers, safety reports and sourcing: the data behind the page. Most people can stop here. Each section below opens on a tap.

Treprostinil Forms and Strengths (How It Comes)

Treprostinil comes in 3 dose forms. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.

Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Treprostinil inactive ingredients by manufacturer.

Injection

Into a vein · Under the skin
Brands Remodulin (the first brand, 2002)
How this form is used
What it may be used for
  • Remodulin and treprostinil injection are used to treat PAH (WHO Group 1) to reduce symptoms associated with exercise
  • Remodulin and treprostinil injection are used in PAH patients who need to transition from epoprostenol, to slow the rate of disease worsening
Important instructions
  • Remodulin and treprostinil injection are given as a continuous infusion — subcutaneous (under the skin) is the preferred route; intravenous (into a vein) is used when subcutaneous is not tolerated
  • Remodulin may be diluted with Sterile Diluent for Remodulin or a similar approved high-pH glycine diluent; treprostinil injection may be diluted with Sterile Diluent for Treprostinil or a similar approved diluent
  • Doses are started low and increased gradually based on response — never stop or sharply reduce the infusion suddenly
  • When transitioning from epoprostenol, Remodulin or treprostinil injection dose is increased slowly while epoprostenol is decreased, under close medical supervision
Available strengths 5 strengths
21 FDA-listed product records ⓘ

Extended-release tablet

By mouth
Brands Orenitram (2013)
How this form is used
What it may be used for
  • Orenitram is used to treat pulmonary arterial hypertension (PAH; WHO Group 1) to delay disease progression and improve exercise capacity
  • Orenitram was studied mainly in patients with WHO functional class II–III PAH symptoms
Important instructions
  • Orenitram must be taken with food every time
  • Swallow Orenitram tablets whole — do not crush, split, or chew them
  • Orenitram is typically taken multiple times per day; doses are spaced several hours apart as directed by your prescriber
  • If transitioning from IV or subcutaneous Remodulin, Orenitram dose is increased while the infusion is gradually decreased — do not manage this transition on your own
Available strengths 5 strengths
16 FDA-listed product records ⓘ

Inhaler

By mouth · Inhaled
Brands Tyvaso (2009) Yutrepia (2025) Tyvaso DPI (2022)
How this form is used
What it may be used for
  • Tyvaso is used to treat pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability
  • Tyvaso is used to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability
  • Tyvaso DPI is used to treat PAH (WHO Group 1) and PH-ILD (WHO Group 3) to improve exercise ability
  • Yutrepia is used to treat PAH (WHO Group 1) and PH-ILD (WHO Group 3) to improve exercise ability
Important instructions
  • Tyvaso is used only with the Tyvaso Inhalation System device and is administered in 4 separate sessions per day, spaced approximately 4 hours apart during waking hours
  • Tyvaso DPI is used only with the Tyvaso DPI Inhaler; each cartridge delivers one inhalation, and treatment is given in 4 sessions per day roughly 4 hours apart
  • Yutrepia capsules are for inhalation only using the supplied inhaler — do not swallow them; they are administered 3 to 5 times per day, with each capsule's contents inhaled in 2 breaths
  • Timing of inhaled sessions can be adjusted around planned activities, as effects diminish over the dosing interval
Available strengths 10 strengths
Show 4 more strengths Show fewer strengths
15 FDA-listed product records ⓘ

Treprostinil on the U.S. Market: Products, Makers and Brands

How Treprostinil appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.

6 companies list 52 Treprostinil product records with the FDA, mostly as injection, extended-release tablet, inhaler; the earliest marketing or approval year on record is 2002. Brand names in the directory today include Orenitram, Tyvaso, Remodulin and 2 more; the rest are generics.

3
Dose forms ⓘ
6
Labelers (makers, repackagers, distributors)
5
Brand names ⓘ
52
FDA-listed product records ⓘ
2002
Earliest FDA record ⓘ

FDA-listed product records by dose form (tablet variants merged) — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

Also listed with the FDA, not a patient dose form: Powder (19) — bulk drug substance and unfinished product sold to compounders and other manufacturers to finish, and multi-item kits. These aren’t counted in the dose-form total above.

United Therapeutics Corporation62%
Alembic Pharmaceuticals Inc.8%
Dr.Reddy's Laboratories Inc.,8%
Liquidia Technologies, Inc.8%
Sandoz Inc8%
Teva Parenteral Medicines, Inc.8%

Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

How Widely Treprostinil Is Used (Medicaid Data)

How many Treprostinil prescriptions Medicaid paid for in Q1–Q4 2025, every brand, strength and form together. Medicaid is one program, so total U.S. use is higher.

15,732
Medicaid prescriptions filled (Q1–Q4 2025)
$215.3M paid by Medicaid, before rebates

How commonly is Treprostinil prescribed? Of the 1,682 medications we measure, Treprostinil ranks #863 by Medicaid prescriptions — more than 49% of them.

Where Treprostinil ranks among the drugs we measure · Q1–Q4 2025 · neighbors ±5

Utilization by Treprostinil product

Pick a strength and form to see its own numbers. Brand and generic versions are counted together.

The 10 mg/mL injectable solution is the most-dispensed Treprostinil product — about 23% of these Medicaid prescriptions.

treprostinil 10 MG/ML Injectable Solution Most dispensed

3,624 Medicaid prescriptions (Q1–Q4 2025) 23% of Treprostinil prescriptions shown $51.5M paid by Medicaid, before rebates ≈ $14,224 per prescription, before rebates

1 of 6 listed NDCs had Medicaid claims. RxNorm 349408

treprostinil 5 MG/ML Injectable Solution

1,680 Medicaid prescriptions (Q1–Q4 2025) 11% of Treprostinil prescriptions shown $14.9M paid by Medicaid, before rebates ≈ $8,859 per prescription, before rebates

2 of 6 listed NDCs had Medicaid claims. RxNorm 349410

treprostinil 1 MG/ML Injectable Solution

1,550 Medicaid prescriptions (Q1–Q4 2025) 10% of Treprostinil prescriptions shown $5.8M paid by Medicaid, before rebates ≈ $3,772 per prescription, before rebates

2 of 6 listed NDCs had Medicaid claims. RxNorm 349407

treprostinil 0.6 MG/ML Inhalation Solution

1,521 Medicaid prescriptions (Q1–Q4 2025) 10% of Treprostinil prescriptions shown $31.8M paid by Medicaid, before rebates ≈ $20,879 per prescription, before rebates

1 of 4 listed NDCs had Medicaid claims. RxNorm 857795

12 HR treprostinil 1 MG Extended Release Oral Tablet

1,383 Medicaid prescriptions (Q1–Q4 2025) 9% of Treprostinil prescriptions shown $12M paid by Medicaid, before rebates ≈ $8,708 per prescription, before rebates

1 of 3 listed NDCs had Medicaid claims. RxNorm 1488674

treprostinil 0.064 MG Inhalation Powder

1,237 Medicaid prescriptions (Q1–Q4 2025) 8% of Treprostinil prescriptions shown $30.9M paid by Medicaid, before rebates ≈ $25,016 per prescription, before rebates

1 of 3 listed NDCs had Medicaid claims. RxNorm 2602764

12 HR treprostinil 0.25 MG Extended Release Oral Tablet

919 Medicaid prescriptions (Q1–Q4 2025) 6% of Treprostinil prescriptions shown $1.9M paid by Medicaid, before rebates ≈ $2,095 per prescription, before rebates

1 of 3 listed NDCs had Medicaid claims. RxNorm 1488670

12 HR treprostinil 5 MG Extended Release Oral Tablet

885 Medicaid prescriptions (Q1–Q4 2025) 6% of Treprostinil prescriptions shown $29.2M paid by Medicaid, before rebates ≈ $33,027 per prescription, before rebates

1 of 3 listed NDCs had Medicaid claims. RxNorm 1858831

treprostinil 2.5 MG/ML Injectable Solution

783 Medicaid prescriptions (Q1–Q4 2025) 5% of Treprostinil prescriptions shown $4.9M paid by Medicaid, before rebates ≈ $6,197 per prescription, before rebates

1 of 6 listed NDCs had Medicaid claims. RxNorm 349409

12 HR treprostinil 2.5 MG Extended Release Oral Tablet

782 Medicaid prescriptions (Q1–Q4 2025) 5% of Treprostinil prescriptions shown $9.6M paid by Medicaid, before rebates ≈ $12,241 per prescription, before rebates

1 of 3 listed NDCs had Medicaid claims. RxNorm 1488678

treprostinil 0.048 MG Inhalation Powder

317 Medicaid prescriptions (Q1–Q4 2025) 2% of Treprostinil prescriptions shown $8.4M paid by Medicaid, before rebates ≈ $26,544 per prescription, before rebates

1 of 3 listed NDCs had Medicaid claims. RxNorm 2602760

12 HR treprostinil 0.125 MG Extended Release Oral Tablet

259 Medicaid prescriptions (Q1–Q4 2025) 2% of Treprostinil prescriptions shown $115,400 paid by Medicaid, before rebates ≈ $446 per prescription, before rebates

1 of 3 listed NDCs had Medicaid claims. RxNorm 1488665

treprostinil 0.032 MG Inhalation Powder

229 Medicaid prescriptions (Q1–Q4 2025) 1% of Treprostinil prescriptions shown $5.6M paid by Medicaid, before rebates ≈ $24,472 per prescription, before rebates

1 of 3 listed NDCs had Medicaid claims. RxNorm 2602756

treprostinil 0.016 MG Inhalation Powder

105 Medicaid prescriptions (Q1–Q4 2025) <1% of Treprostinil prescriptions shown $2.6M paid by Medicaid, before rebates ≈ $25,136 per prescription, before rebates

1 of 3 listed NDCs had Medicaid claims. RxNorm 2602751

treprostinil 0.0795 MG Inhalation Powder

65 Medicaid prescriptions (Q3–Q4 2025) <1% of Treprostinil prescriptions shown $1.7M paid by Medicaid, before rebates ≈ $26,806 per prescription, before rebates

1 of 1 listed NDCs had Medicaid claims. RxNorm 2714670

treprostinil 0.106 MG Inhalation Powder

43 Medicaid prescriptions (Q2–Q4 2025) <1% of Treprostinil prescriptions shown $743,412 paid by Medicaid, before rebates ≈ $17,289 per prescription, before rebates

1 of 1 listed NDCs had Medicaid claims. RxNorm 2714674

treprostinil 0.053 MG Inhalation Powder

41 Medicaid prescriptions (Q3–Q4 2025) <1% of Treprostinil prescriptions shown $432,802 paid by Medicaid, before rebates ≈ $10,556 per prescription, before rebates

1 of 1 listed NDCs had Medicaid claims. RxNorm 2714666

treprostinil 0.0265 MG Inhalation Powder

25 Medicaid prescriptions (Q2–Q4 2025) <1% of Treprostinil prescriptions shown $274,301 paid by Medicaid, before rebates ≈ $10,972 per prescription, before rebates

1 of 1 listed NDCs had Medicaid claims. RxNorm 2714659

Other Treprostinil products: packs and listings not matched to one strength and form

284 Medicaid prescriptions (Q1–Q4 2025) 2% of Treprostinil prescriptions shown $2.8M paid by Medicaid, before rebates ≈ $9,739 per prescription, before rebates

3 of 74 listed NDCs had Medicaid claims.

Dollars are what Medicaid paid before the rebates drug makers send back, so its real cost is lower.

Source: Medicaid State Drug Utilization Data (CMS), all states. 23 of the 133 listed Treprostinil NDCs had Medicaid claims.

Compare Treprostinil Products

A representative set of FDA-listed product records for Treprostinil — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)

Showing 52 of 52 products — FDA National Drug Code Directory. See every product, package size and price: browse all 52 Treprostinil NDCs →

Treprostinil Recall History

A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.

The FDA’s enforcement reports list no Treprostinil recalls since July 2021.

✅No Treprostinil recalls on record since July 2021

Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Nov 19, 2026.

Treprostinil in RxNorm: From Ingredient to Every Form and Strength

RxNorm is the U.S. National Library of Medicine’s standard name for every version of a medicine, the code pharmacy and prescribing systems share. This page starts from one ingredient (IN); each dose form (SCDF) branches from it, and each exact strength (SCD) from its form. Combination products are separate concepts with their own pages.

Dose forms
4
Strengths
20
Forms in current FDA listings
2 of 4
In current FDA listings No current FDA listing
Ingredient (IN) Treprostinil RxCUI 343048
  1. Dose form (SCDF) Extended Release Oral Tablet RxCUI 1488664
    In current FDA listings
    Its 5 strengths (SCD)
    • 0.125 mg 12-hour RxCUI 1488665
    • 0.25 mg 12-hour RxCUI 1488670
    • 1 mg 12-hour RxCUI 1488674
    • 2.5 mg 12-hour RxCUI 1488678
    • 5 mg 12-hour RxCUI 1858831
  2. Dose form (SCDF) Inhalation Powder RxCUI 2602750
    No current FDA listing
    Its 9 strengths (SCD)
  3. Dose form (SCDF) Inhalation Solution RxCUI 2108557
    No current FDA listing
    Its strength (SCD)
  4. Dose form (SCDF) Injectable Solution RxCUI 385082
    In current FDA listings
    Its 5 strengths (SCD)

RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.

What Medicaid Pays for Treprostinil

CMS’s weekly pharmacy survey (NADAC) has no price for Treprostinil, so here is what state Medicaid programs paid for it over the four quarters through Q1 2026, before rebates. It is not your price at the counter.

No price was found for Treprostinil injections or inhalers, so the prices below are for the extended-release tablets only.

FormStrengthVersion What Medicaid paid
Extended-release tablet · Oral 0.125 mg Orenitram (brand) $8.17 per tablet NDC details & Medicaid use
Extended-release tablet · Oral 0.25 mg Orenitram (brand) $15.60 per tablet NDC details & Medicaid use
Extended-release tablet · Oral 1 mg Orenitram (brand) $60.20 per tablet NDC details & Medicaid use
Extended-release tablet · Oral 2.5 mg Orenitram (brand) $155.32 per tablet NDC details & Medicaid use
Extended-release tablet · Oral 5 mg Orenitram (brand) $307.42 per tablet NDC details & Medicaid use
Why it helps: it shows whether the drug itself is cheap or costly, and whether a cash price you are quoted is in a reasonable range. What you pay also depends on your insurance and pharmacy.

Source: CMS State Drug Utilization Data, total paid divided by units paid for across every state, for each strength’s packages.

Treprostinil Brand Names

Treprostinil has 5 brand names on record: Orenitram, Tyvaso, Remodulin, Yutrepia and others. A brand name is one company's name for the medicine; a generic has the same active ingredient under its generic name.

Orenitram 2013 Tyvaso 2009 Remodulin the first brand, 2002 Yutrepia 2025 Tyvaso DPI 2022

Who Makes Treprostinil: Manufacturers and Labelers

6 companies list Treprostinil products with the FDA. By number of product records, the largest are United Therapeutics Corporation, Alembic Pharmaceuticals Inc., Dr.Reddy's Laboratories Inc.,. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.

United Therapeutics Corporation 32 Alembic Pharmaceuticals Inc. 4 Dr.Reddy's Laboratories Inc., 4 Liquidia Technologies, Inc. 4 Sandoz Inc 4 Teva Parenteral Medicines, Inc. 4

Sources for This Treprostinil Page

Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.

📄
FDA-filed drug labels (SPL) Uses, dosing, warnings & side effects from SPL records retrieved through openFDA; the linked representative set can be verified on DailyMed. Prescribing information dated Feb 13, 2025, the label version this page reads. A label changes when the FDA approves new uses, doses or warnings, so this is not the day the page itself last changed. Read the full label on DailyMed
🏭
Forms, brands & labelersAggregated from ingredient-matched FDA National Drug Code Directory product records for Treprostinil.
📈
Real-world reportsThe FDA Adverse Event Reporting System (FAERS), served through openFDA.
🚨
Recalls & shortagesopenFDA drug-enforcement reports and the FDA drug-shortage database.

Where this information comes from

The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 5 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source.

Clinical labels in scope
5
Finished products in the current FDA directory
52
Companies listing them (makers, repackagers, distributors)
6
FDA labeler codes behind them ⓘ
6
Linked representative label ⓘ
Alembic Pharmaceuticals Inc.
Linked label effective
Feb 13, 2025
Composite sections available
21
Linked SPL Set ID
4a684b13-669d-4721-8ed4-30cc7762b0b8
Linked SPL Document ID
5384ef7c-88cc-4ab7-8eb7-627eba752f9d
Open the linked representative label on DailyMed ↗

How this page is built

HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Alembic Pharmaceuticals Inc. is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →